Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System is Significant Step Forward for Millions with Type 1 Diabetes

Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System is Significant Step Forward for Millions with Type 1 Diabetes PR Newswire WEST CHESTER, Pennsylvania, June 11, 2012 - System in Development from Animas-JDRF Partnership Successfully Detects Highs and Lows, and Shown to Safely and Automatically Adjust Insulin Delivery in Clinical Setting WEST CHESTER, Pennsylvania, June 11, 2012 /PRNewswire/ -- Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely. The HHM System included a continuous, subcutaneous insulin pump, a continuous glucose monitor (CGM) and special software used to predict changes in blood glucose. The study was conducted by Animas Corporation in collaboration with JDRF as part of an ongoing partnership to advance the development of a closed-loop artificial pancreas system for patients with Type 1 diabetes. "The successful completion of this study using the HHM System in a human clinical trial setting is a significant step forward in the development of an advanced first-generation artificial pancreas system," said Dr.